Real-World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE-RWD).
Real-world evidence confirms a newer kidney-protective drug works safely in diabetic kidney disease patients outside clinical trials.
First real-world multicenter Spanish evidence for finerenone (non-steroidal MRA) effectiveness and safety in T2DM with CKD, providing confirmatory data beyond the FIDELIO-DKD and FIGARO-DKD phase 3 trials in a routine clinical population. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- multicenter retrospective observational study (MEDFINE-RWD, Spain)
- Category
- glp1_sglt2_cardiometabolic
- Maturity
- Validated
- Journal
- Diabetes Obes Metab
Why it surfaced
Finerenone represents a paradigm shift in CKD/T2DM cardiorenal protection, but real-world evidence is sparse. This multicenter study provides the first substantial Spanish real-world dataset for this drug class, relevant to formulary decisions and clinical practice guidelines.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.